Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.
Department of Microbiology, Radiology, Pediatrics and Public Health, ARAID Foundation/University of Zaragoza, Zaragoza, Spain.
Oncoimmunology. 2022 Jul 6;11(1):2096359. doi: 10.1080/2162402X.2022.2096359. eCollection 2022.
The contribution of the T cell-related inhibitory checkpoint PD-1 to the regulation of NK cell activity is still not clear with contradictory results concerning its expression and role in the modulation of NK cell cytotoxicity. We provide novel key findings on the mechanism involved in the regulation of PD-1 expression on NK cell membrane and its functional consequences for the elimination of cancer cells. In contrast to freshly isolated NK cells from cancer patients, those from healthy donors did not express PD-1 on the cell membrane. However, when healthy NK cells were incubated with tumor target cells, membrane PD-1 expression increased, concurrent with the CD107a surface mobilization. This finding suggested that PD-1 was translocated to the cell membrane during NK cell degranulation after contact with target cells. Indeed, cytosolic PD-1 was expressed in freshly-isolated-NK cells and partly co-localized with CD107a and GzmB, confirming that membrane PD-1 corresponded to a pool of preformed PD-1. Moreover, NK cells that had mobilized PD-1 to the cell membrane presented a significantly reduced anti-tumor activity on PD-L1-expressing-tumor cells and , which was partly reversed by using anti-PD-1 blocking antibodies. Our results indicate that NK cells from healthy individuals express cytotoxic granule-associated PD-1, which is rapidly mobilized to the cell membrane after interaction with tumor target cells. This novel finding helps to understand how PD-1 expression is regulated on NK cell membrane and the functional consequences of this expression during the elimination of tumor cells, which will help to design more efficient NK cell-based cancer immunotherapies.
T 细胞相关抑制性检查点 PD-1 对 NK 细胞活性的调节作用尚不清楚,其在 NK 细胞细胞毒性调节中的表达和作用存在矛盾的结果。我们提供了关于 PD-1 在 NK 细胞膜上表达的调节机制及其对癌细胞消除的功能后果的新的关键发现。与来自癌症患者的新鲜分离的 NK 细胞不同,来自健康供体的 NK 细胞不在细胞膜上表达 PD-1。然而,当健康的 NK 细胞与肿瘤靶细胞孵育时,膜 PD-1 的表达增加,同时伴随着 CD107a 表面的动员。这一发现表明,PD-1 在与靶细胞接触后 NK 细胞脱颗粒时被转运到细胞膜上。事实上,细胞质 PD-1 在新鲜分离的 NK 细胞中表达,并与 CD107a 和 GzmB 部分共定位,证实膜 PD-1 对应于预先形成的 PD-1 池。此外,将 PD-1 动员到细胞膜上的 NK 细胞对表达 PD-L1 的肿瘤细胞的抗肿瘤活性显著降低,并且通过使用抗 PD-1 阻断抗体部分逆转。我们的结果表明,来自健康个体的 NK 细胞表达与细胞毒性颗粒相关的 PD-1,其在与肿瘤靶细胞相互作用后迅速被动员到细胞膜上。这一新发现有助于理解 PD-1 在 NK 细胞膜上的表达是如何调节的,以及这种表达在消除肿瘤细胞过程中的功能后果,这将有助于设计更有效的基于 NK 细胞的癌症免疫疗法。